Sinovac Biotech said on Saturday that its unit's COVID-19 vaccine has been formally approved for use by the general public by China's medical products regulator.
It marks the second COVID-19 vaccine green-lighted for public use in China, after a shot developed by a Beijing institute affiliated to state-owned China National Pharmaceutical Group (Sinopharm) was approved in December.
Prior to the approvals, both vaccines have already been used in China's vaccination program mainly targeting key groups deemed to be at higher risk of exposure to the virus.
Indonesia, Turkey, Brazil, Chile, Colombia, Uruguay, and Laos have granted emergency authorizations for the CoronaVac vaccine developed by Sinovac Life Sciences, Sinovac said in a news release.
The approval is based on the two-month results from late-stage clinical trials overseas, from which the final analysis data has not yet been obtained, Sinovac said.
Iran says it is reviewing US proposal to end war
UN Human Rights Council adopts resolution condemning Iranian attacks
Russian attacks kill two in Ukraine's Kharkiv
Kuwait foils terror plot targeting state leaders
Iran rejects Trump's talk of negotiation as Israel and Iran launch airstrikes
Cyprus has opened discussion with UK over its bases, president says
Netanyahu seeks to avoid snap vote as Iran war gives no boost in polls
Luxury Paris hotel near Elysee reopens after fire forces brief closure
